109 results about "Protein recombinants" patented technology

Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.

Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.

The invention provides African swine fever P30 protein recombinant baculovirus expression vector and a preparation method thereof. The method comprises: amplifying in plasmid PCR-4TOPO-P30 of ASFV (African swine fever virus) P30 full-length gene to obtain P39 gene, linking the amplified P30 gene to a baculovirus vector pFastBac 1 to construct recombinant baculovirus vector pFastBac1-ASFV-P30, converting into competent Escherichia coli cells DH10Bac to obtain recombinant shuttle bacmid rBacmid-ASFV-P30, transfecting to insect cells Sf9 after verification is correct to obtain recombinant baculovirus, and passage amplifying the recombinant baculovirus, linking baculovirus high in titer and containing ASFV P30 gene to High Five insect cells for eukaryotic expression of ASFV P30. The African swine fever P30 protein recombinant baculovirus expression vector is constructed by using the method, a recombinant baculovirus expression system is used to express African swine fever P30 protein in insect cells, and basis is laid for African swine fever ELISA (enzyme-linked-immunosorbent serologic assay) detections.

Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (POI) that has an immunoglobulin CH3 domain and / or substituted CH3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. The invention also provides recombinant antigen-binding proteins that are capable of recognizing and binding to proteins of interest that contain a CH3 domain and / or a modified CH3 domain, such as a CH3 domain with or without amino acid substitutions at H95 and Y96 (IMGT).

The invention discloses a novel coronavirus N protein recombinant antigen and application thereof, and belongs to the field of protein immunoassay reagents. The recombinant antigen is a protein, and the amino acid sequence of the recombinant antigen is shown as SEQ ID NO.1 or 3. The recombinant antigen is used for preparing a reagent for detecting an N protein antibody; and compared with an N protein full-length antigen, the thermal stability of the reagent and the detection accuracy can be improved.

Recombinant forms of isolated and purified delta opioid receptors and methods to screen for compounds interactive with delta opioid receptors are described.

The invention provides a preparation method and method of hog cholera-ring-mixed antigen, hog cholera-ring subunit vaccines and a preparation method thereof, and relates to the technical field of biological products. The method comprises the following step of inoculating virus mixing liquid of hog cholera E2 protein recombinant viruses and porcine circovirus II-type Cap protein recombinant virusesinto a cell culture for culturing to obtain the mixed antigen. The preparation method of the hog cholera-ring-mixed antigen, hog cholera-ring subunit vaccines relieves the complicated working procedures that in a conventional technology, two kinds of viruses are cultured in batches and compounded after being gained. The valence of antibody after the vaccines prepared from the mixed antigen are used for vaccine immunity is high.

Recombinant nucleic acid molecules are constructed with a first sequence encoding a transgene under the control of regulatory sequences that direct expression of the transgene product in a hematopoietic stem cell, or a progenitor cell therefrom or cell differentiated therefrom. In one embodiment, the cell which expresses the transgene is a secretory cell. The cell is a megakaryotic progenitor cell, or a cell further differentiated therefrom, such as a platelet. The cell is a granulocyte / macrophage progenitor cell or a cell further differentiated therefrom, such as a mast cell or neutrophils. Such host cells containing the molecule or the molecule itself are employed in methods for treating or preventing infection, inflammation or vascular injuries or any disorders involving or mediated by cells of the hematopoietic lineage.

The invention relates to an interest protein preparation method and a purpose of the interest protein preparation method. The interest protein preparation method comprises the steps of obtaining interest protein nucleotide sequence fragments, constructing interest protein recombinant expression vectors, expressing interest protein in an inducible mode, purifying the interest protein and cutting purified products. The fronts of the interest protein nucleotide sequence fragments are inserted into monomer cutting recognition sites. Preferably, the upper streams of the interest protein nucleotide sequence fragments are introduced into kex2 enzyme cutting sites, and the down streams of the interest protein nucleotide sequence fragments are introduced into hydroxylamine hydrochloride enzyme cutting sites. The interest protein is obtained through sequence of event (SOE) technology, and is introduced into monomer cutting recognition sites through primers. The interest protein can be human nerve growth factors such as thymosin, tiger stripe pancreatic polypeptide and tiger stripe analgesic peptide. By adopting the interest protein preparation method, obtained interest protein is high in expression quality and easy to purify. Genetic expression products are interest protein monomer, no extra amino acid residue is carried, and thus not only is the good biology activity of interest protein products ensured, but also multicopy cutting cost is saved, the purification is simple and the mass production is facilitated.

Recombinant papillomavirus capsid proteins that are capable of self assembly into capsomer structures and viral capsids that comprise conformational antigenic epitopes are provided. The capsomer structures and viral capsids, consisting of the capsid proteins that are expression products of a bovine, monkey or human papillomavirus L1 conformational coding sequence proteins, can be prepared as vaccines to induce a high titer neutralizing antibody response in vertebrate animals. The self assembling capsid proteins can also be used as elements of diagnostic immunoassay procedures for papillomavirus infection.

The invention relates to recombinant bacillus subtilis for expressing S protein of transmissible gastroenteritis of swine virus (TGEV), and belongs to the fields of biotechnology and genetic engineering. According to the recombinant bacillus subtilis disclosed by the invention, a TGEV S protein recombinant bacillus subtilis integrated expression plasmid pIncotGSR is successfully constructed, and the expression plasmid is successfully transformed into bacillus subtilis WB800 through electric shock. Based upon Western-blot verification, the TGEV S protein can be successfully expressed in the recombinant bacillus subtilis. An effective TGEV specific immune response level can effectively generate in the body of a one-month-old piglet through stimulation of oral immunization. The recombinant bacillus subtilis is expected to be developed as a genetic engineering oral vaccine for preventing transmissible gastroenteritis of swine.

Recombinant adenoviruses comprising modified fiber proteins which expand the tropism of the adenovirus in comparison to wild-type virus are disclosed. The modified fiber proteins described herein contain a peptide ligand for a cell surface binding site other than CAR comprising a 14 amino acid core sequence containing both fixed and variable amino acid residues. The invention includes isolated nucleic acid molecules encoding the modified adenovirus fiber proteins disclosed, as well as recombinant vectors and host cells containing said nucleic acid molecules. Methods of identifying peptide ligands that bind to cell binding sites other than CAR are included comprising screening a phage-display library of peptide ligands expressed within an adenovirus fiber knob context on CAR-negative cells. Recombinant adenoviruses of the present invention will increase the ability of an adenovirus to transduce important cell and tissue targets as part of a gene therapy / gene vaccination regime that have been shown to be refractory to adenoviral infection.

The invention provides a recombinant baculovirus AcBacDeltaCC-GP41 and an establishment method thereof and relates to the technical field of biological engineering technique and pharmacological. The recombinant baculovirus is CCTCC NO.V200702 and the establishment method comprises the steps: the expression system of Bac-to-Bac baculovirus developed by INVITROGEN Company is used, an AcMNPV baculovirus carrier is selected, then double-deletion shuttle carrier Ac-bacDeltaCC is obtained through a reformation of an AcMNPV shuttle carrier and last the recombinant baculovirus AcBacDeltaCC-GP41 is obtained by using insect cell expression system. The invention has the advantages that the virus is the protein recombinant virus which can high effectively express HIV-1 and has the full length of GP41 and the structure and function thereof are close to natural protein and beneficial for studying natural conformation of GP41 and paves the solid foundation for fully explaining mechanism of HIV-1 entering cells and the immune diagnose and vaccine development based on GP41 and the prevention and curing of AIDS.